Table 2. Monthly market share for oral antidiabetic and antihypertensive medicines, generic and non-generic, and changes in market share level and trend by stage of the Farmácia Popular program, Brazil, 2007 to 2012.

Market share measure a	Baseline		AFP II (April 2009)				SNTP (February 2011)
	MS (Jan 2007)	Trend	MS (Mar 2009)	Level change after policy (95%CI)	Trend change after policy (95%CI)	% relative change in MS (Apr 2010)	MS (Jan 2011)	Level change after policy (95%CI)	Trend change after policy (95%CI)	% relative change in MS (Feb 2012)
Diabetes
A) AFP volume as a proportion of market volume: generics b	28.5	1.1	57.8	-21.3 (-27.6 – -15.0)	-1.6 (-2.1 – -1.2)	-54.4	28.0	32.3 (25.5 – 39.0)	1.7 (1.2 – 2.2)	242.6
B) AFP volume as a proportion of market volume: non-generics b	6.9	2.0	61.7	-27.5 (-32.9 – -22.1)	-2.6 (-3.0 – -2.2)	-63.9	26.6	24.4 (18.6 – 30.2)	1.4 (1.0 – 1.9)	209.7
Hypertension
C) AFP volume as a proportion of market volume: generics b	22.6	1.0	48.4	-22.3 (-28.8 – -15.8)	-1.3 (-1.8 – -0.8)	-59.9	21.4	31.8 (24.9 – 38.7)	1.4 (0.9 – 1.9)	277.0
D) AFP volume as a proportion of market volume: non-generics b	2.8	2.1	59.5	-31.7 (-37.4 – -26.1)	-2.8 (-3.2 – -2.4)	-71.5	18.8	14.4 (8.4 – 20.5)	1.3 (0.8 – 1.7)	279.0

AFP: Aqui tem Farmácia Popular private sector program, phases I and II; AFP-II – reduction of reference prices and consequent increase in patient copayment from April 2009 to January 2011; SNTP: Saúde não tem preço (Health has no price) phase. All covered medicines for hypertension and diabetes being free of charge to patients starting from February 2011; IQVIA: QuintilesIMS™; MS: Market share

^a Market share (MS) is calculated as the volume of medicines sold in AFP divided by the total market volume sold in IQVIA data, for oral antidiabetic and antihypertensive generic and non-generic medicines that are covered in the AFP program; They represent the indicators a and b presented in the Table 1.

^b A, B, C, and D correspond to the graphs in Figure 3.

Values in bold present p < 0.05